Literature DB >> 31412193

Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply.

Fabrice André1, David Mills2, Tetiana Taran2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31412193     DOI： 10.1056/NEJMc1907856

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.

Authors:  Alicia Okines; Tazia Irfan; Bernice Asare; Kabir Mohammed; Peter Osin; Ashutosh Nerurkar; Ian E Smith; Marina Parton; Alistair Ring; Stephen Johnston; Nicholas C Turner
Journal:  Breast Cancer Res Treat       Date:  2022-02-04       Impact factor: 4.872

2.  Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines.

Authors:  Monika Lukoseviciute; Henrietta Maier; Eleni Poulou-Sidiropoulou; Erika Rosendahl; Stefan Holzhauser; Tina Dalianis; Ourania N Kostopoulou
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

Review 3.  Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.

Authors:  Tsvetalina Tankova; Elżbieta Senkus; Maria Beloyartseva; Simona Borštnar; Doina Catrinoiu; Mona Frolova; Alinta Hegmane; Andrej Janež; Mladen Krnić; Zoltan Lengyel; Yiola Marcou; Laura Mazilu; Bela Mrinakova; Ruth Percik; Katarina Petrakova; Gábor Rubovszky; Margarita Tokar; Eduard Vrdoljak
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.